Yazar "Deveci Ö." seçeneğine göre listele

Listeleniyor 1 - 4 / 4
  • [ X ]
    Öğe
    Hbsag, anti-HCV and anti-HIV seroprevalence among blood donors in southeastern anatolia, Turkey, 2011-2015
    (EDIMES Edizioni Medico Scientifiche, 2019) Dayan S.; Özekinci T.; Bekçibaşi M.; Deveci Ö.
    Transmission of infections through blood and blood product transfusion is a serious healthcare problem. There are insufficient up-to-date data about seroprevalence of HBsAg, anti-HCV and anti-HIV 1/2 among healthy blood donors in Turkey. We aimed to investigate the seroprevalence of HBsAg, anti-HCV and anti-HIV 1/2 in Southeastern Anatolia, Turkey. HBsAg, anti-HCV, and anti-HIV 1/2 analysis results among blood donors who applied to Dicle University Faculty of Medicine, Diyarbakir District Blood Centre, between January 1, 2011 and December 31, 2015 were retrospectively evaluated. HBsAg, anti-HCV, and anti-HIV 1/2 screenings were performed using a fully automated device with the microparticle enzyme immunoassay method (MEIA). The chi-square (?²) test was applied to variables. Among the donors, 1607 (1.73%) were HBsAg-positive, 255 (0.27%) were anti-HCV-positive and two (0.0021%) were positive for anti-HIV 1/2. HBsAg positivity rates by years were 2.50% in 2011, 1.92% in 2012, 1.74% in 2013, 1.53% in 2014 and 1.27% in 2015 (p<0.001). HBsAg-positivity was 0.78% for the donors between 18-24 years of age, 1.90% for those between 25-49 years of age and 3.92% for donors over the age of 49 (p<0.001). Anti-HCV positivity rates were as follows: 0.35% in 2011, 0.34% in 2012, 0.29% in 2013, 0.23% in 2014 and 0.16% in 2015 (p<0.001). Verified anti-HIV 1/2 positivity was observed for only two donors (0.0021%) within five years. HBsAg and anti-HCV positivity were observed to decrease significantly over the years and were significantly lower among younger donors. © 2019, EDIMES Edizioni Medico Scientifiche. All rights reserved.
  • [ X ]
    Öğe
    In vitro antimicrobial susceptibility pattern among stenotrophomonas maltophilia strains isolated from clinical specimens
    (Duzce University Medical School, 2014) Tekin A.; Dal T.; Tekin R.; Deveci Ö.; Demirkaya S.; Mete M.; Dayan S.
    Aim: In this study, the determination of in vitro antimicrobial susceptibility rates among Stenotrophomonas maltophilia strains isolated from clinical specimens was aimed. Method: A total of 60 S. maltophilia strains isolated from various clinical specimens sent to Dicle University Hospital clinical microbiology laboratory between January 2006 and September 2011 were included retrospectively in this study. Urine samples were inoculated onto 5% sheep blood agar and Eosin-Methylene Blue (EMB) agar media, quantitatively; other clinical samples were inoculated, qualitatively. Identification of S. maltophilia isolates was performed by conventional methods and fully automated microbiology system. Antimicrobial susceptibility tests were performed by Kirby-Bauer’s disk diffusion method and by broth dilution. Results: A total of 60 S. maltophilia strains isolated from clinical specimens as 24 urine, 15 blood, 11 sputum, four synovial fluids, three cerebrospinal fluids, two wound swabs and one middle ear materials. The resistance rates against antibiotics were detected as 85% (n=51) for piperacillin-tazobactam, 75% (n=45) for levofloxacin, 73% (n=44) for ciprofloxacin, 57% (n=34) for trimethoprim-sulfamethoxazole, 5% (n=3) for meropenem and imipenem, and 0% (n=0) for amikacin. Conclusion: In this study, it was detected that piperacillin-tazobactam can be used as an alternative option other than trimethoprim-sulfamethoxazole, for the treatment of infections due to S. maltophilia at least in our region. © 2012 Düzce Medical Journal.
  • [ X ]
    Öğe
    In vitro efficiency of ertapenem among escherichia coli strains isolated from clinical specimens
    (2013) Tekin A.; Deveci Ö.; Dal T.; Tekin R.; Bacalan F.; Akpolat N.
    In this study, in vitro efficiency of ertapenem and extanded-spectrum beta-lactamase (ESBL) producing among Escherichia coli strains isolated from clinical specimens were investigated. 334 E. coli strains isolated from clinical specimens that sent to Dicle University Hospital clinical microbiology laboratory between December 2010 and August 2011 were included in this study. Identification of isolates was performed by conventional methods and a fully automated microbiology system. Antimicrobial susceptibility testing of strains was performed by Kirby- Bauer's disc diffusion method and E-test method. Double-disk synergy method was used for the detection of ESBL-producing. 334 E. coli strains were isolated from clinical specimens as 233 (69.8%) urine, 55 (16.4%) blood, 32 (9.6%) wound swabs and 14 (4.2%) others. In 177 (53%) from 334 E. coli strains were determined the ESBL activity. Ertapenem sensitivity rate among strains was determined as 93.4%. Although there was no resistance to ertapenem in ESBL-non-producing strains, ertapenem resistance rate was found as 12.4% in ESBL-producing strains. The high resistance rate for ertapenem in ESBL-producing strains according to the ESBL-non-producing strains was found to be statistically significant (p<0.001). In the light of present study, we think as the better option of ertapenem which has got a high sensitivity rate in the treatment with antimicrobial agents of infections caused by ESBL-producing E. coli strains at least in our hospital.
  • [ X ]
    Öğe
    Tenofovir disoproxil fumarate treatment in HbeAg-positive patients
    (EDIMES Edizioni Medico Scientifiche, 2015) Ayaz C.; Çelen M.K.; Dal T.; Deveci Ö.; Bayan K.; Mert D.; Oruç E.
    Tenofovir disoproxil fumarate (Tenofovir DF) is a nucleotide analogue. This multicentre study reports retrospectively the long-term efficacy and safety data with tenofovir DF treatment in nucleosid(t)e-naive, hepatitis B e antigen (HBeAg)-positive chronic hepatitis B patients. Thirty-one patients (11 females, 20 males) received 245 mg tenofovir DF per diem. All patients’ initial serum hepatitis B virus (HBV) DNA levels were over 2,000 IU/ml. Serum alanine aminotransferase (ALT) levels, HBeAg, hepatitis B e antibodies (anti-HBe), hepatitis B surface antigen (HBsAg), hepatitis B surface antibodies (Anti-HBs), HBV DNA, creatinine and urea levels were evaluated at baseline, and at weeks 12, 24, 48 and 96 during therapy. Thirtyone patients completed 96 weeks of treatment. Mean age was 37.6±9.4 years. The initial mean value of ALT was 79±39.9 IU/L. At baseline, mean of fibrosis (Ishak) of liver biopsies was 2.3±0.7. Two of the patients (5.9%) achieved HBV DNA<300 copy at week 12 of treatment and 97.1% at week 96. HBeAg loss was observed in 6.7% of patients. At week 96, HBsAg loss was not observed in any of the patients. Mean ALT at week 48 was 32.7 U/L, at week 96 32.6 U/L. Renal safety was good. Creatinine remained stable. Tenofovir DF was well tolerated and produced potent, continuous viral suppression with increasing HBeAg loss. © 2015, EDIMES Edizioni Medico Scientifiche. All rights reserved.